An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi method was used. CRCLM is defined as liver metastases detected at or before diagnosis of the primary CRC. Early and late metachronous metastases are defined as those detected 612 months and >12 months after surgery, respectively. To provide information on potential curability, use of high-quality contrast-enhanced computed tomography (CT) before chemotherapy is recommended. Magnetic resonance imaging is increasingly being used preoperatively to aid detection of subcentimetric metastases, 
Introduction
Colorectal cancer (CRC) has become the third most common malignancy worldwide in terms of incidence and fourth for cancer mortality [1] . At CRC diagnosis, 20-25% of patients have stage IV disease [2] [3] [4] [5] , in which synchronous CRC liver metastases (CRCLM) are present in 15-25% of cases [6] and metastases are confined to the liver in 70-80% of these cases [7] . Surgical resection is the most effective treatment approach for CRCLM, but only a minority of patients are suitable for upfront surgery [8] . Although data from the population-based Burgundy registry have to be interpreted with caution as they are from the period 1976 to 2000, they show that resection for cure of CRCLM is performed significantly less often in cases of synchronous metastases than for metachronous metastases (6.3% vs 16.9%, respectively) [7] . The prognosis for patients with untreated CRCLM is poor; in the Burgundy registry, fewer than 30% of patients with untreated disease were alive after 1 year and fewer than 5% survived 5 years after diagnosis [7] . Data from this registry also showed that 5-year survival rates were shorter with synchronous than with metachronous CRCLM (3.3% vs 6.1%, respectively) [7] , although some studies have shown no significant difference [9] . The reported percentage of synchronous CRCLM is increasing compared with metachronous metastases [10] , probably due to improved imaging techniques leading to earlier diagnosis. However, different definitions of synchronous metastases can be found in the literature and adoption of a standardized definition is needed to clarify future reporting.
An international multidisciplinary group of experts in managing liver metastases (LM) from CRC (the EGOSLIM group) convened to discuss synchronous metastases and their management. In the absence of data from randomized controlled trials (RCTs) to guide decisions, the aims of the meeting were to agree: a definition for synchronous CRCLM; imaging for their detection; pathological evaluation and reporting; resectability of CRCLM; timing for surgery of the primary tumour and CRCLM; chemotherapy and treatment regimens; postoperative management; and the multidisciplinary approach to management. Through dissemination of the consensus decisions reached, it is hoped that the management of patients with synchronous CRCLM will be optimized.
Methods
The international consensus panel comprised experts from the USA, Europe and Asia in the treatment of patients with CRCLM and included one coordinator, five medical oncologists (including two gastroenterologists), five hepatic surgeons, one colorectal surgeon, two radiologists, one pathologist and one molecular gastrointestinal oncologist. All important aspects of multidisciplinary team (MDT) management of synchronous CRCLM were identified before the meeting by the coordinator and referred to experts for presentation at the meeting. Meta-analyses, RCTs and studies evaluating clinical practice in the management of synchronous CRCLM were identified and reviewed before, and discussed during, the meeting. A modified Delphi method was used to aid achievement of a consensus (see Appendix 1) [11] . Recommendations were formulated when approved by all or a large majority of the panel members and are summarized in Table 1 . Strength of recommendations was attributed based on the Strength of Recommendation Taxonomy [12] . For all recommendations, there is an assumption that all imaging, surgery and therapy are optimal. Some panel members were not present for the whole meeting and some members chose to abstain from voting on some questions not in their area of expertise.
Definition and prognosis of synchronous LM
Different definitions of synchronous CRCLM exist. Although, by definition, all metastases are synchronous (occult or detectable at diagnosis), most definitions include detection at or before diagnosis or surgery of the primary tumour [13] , whilst some also include metastases detected up to 3 [14, 15] , 4 [16] or 6 months [17, 18] following diagnosis.
With regard to prognosis of resected synchronous LM, a disease-free interval from the primary to discovery of the LM of less than 12 months has been associated with a hazard ratio of 1.3 for disease recurrence [19] . The majority of the panel (14/15, 93%) agreed that synchronicity is a sign of poor prognosis, irrespective of the treatment. In the ongoing LiverMetSurvey international registry, an international registry of patients undergoing surgery for CRCLM, [20] , available current data show a significant difference in survival when metastases are detected at or 1 month before diagnosis vs 0-3 months after diagnosis (p < 0.0001); 5-year survival is 39% vs 44%, respectively (Fig. 1) . Survival rates are not significantly different between patients in whom metastases are detected at or 1 month before vs up to 6 months or 6-12 months after diagnosis (Fig. 1) . However, survival rates are significantly different between patient groups when metastases are detected at or within 1 month before diagnosis vs more than 12 months after the primary diagnosis (p < 0.0001). Although lacking confirmatory molecular biological information, these data support the division of LM into those diagnosed at the following time points: at or before the time of diagnosis; 0-12 months following diagnosis; and more than 12 months following diagnosis.
Consensus recommendations
Synchronous CRCLM have less favorable cancer biology and expected survival than metachronous, particularly late metachronous, metastases. Synchronous CRCLM should be termed 'synchronously detected liver metastases'. This is defined as LM detected at or before diagnosis of the primary tumour. Early metachronous metastases are considered to be those detected within 12 months after diagnosis or surgery of the primary. Late metachronous metastases are considered to be those detected more than 12 months after diagnosis or surgery of the primary.
The role of imaging in the detection of synchronous CRCLM
Imaging is used to detect and characterize liver nodules and evaluate resectability. Imaging modalities include ultrasound, contrast-enhanced ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET)-CT. The best methods for staging are CT and MRI. A review of the literature indicates that MRI is more sensitive than CT for subcentimetre liver lesions [21] and after neoadjuvant chemotherapy [22] , and that a thoraco-abdominal CT is the best option for initial staging [12] . Appraisal of published methods shows that a quadri/triphasic technique, optimal contrast administration and scanning parameters providing high spatial and contrast resolution show superior CT accuracy than generally reported in the literature [23] [24] [25] 22] . Regardless of the technique, the need for high-quality baseline imaging before any chemotherapy cannot be stressed enough. Lesions are easier to see before chemotherapy and treatment response helps in characterization. MRI should be performed when characterization is difficult (e.g. when there are many small nodules including both metastatic and benign lesions) and when the liver is fatty [26] . Given the current state of technical development and experience, high-quality MRI and CT can be used for preoperative imaging.
In an RCT of patients with resectable CRCLM (not specifically synchronous), the use of PET-CT compared with CT alone did not result in significant changes in surgical management [27] . A role [12] : A, recommendation based on consistent and good-quality patient-oriented evidence; B, recommendation based on inconsistent or limited-quality patient-oriented evidence; C, recommendation based on consensus, usual practice, opinion, disease-oriented evidence or case series for studies of diagnosis, treatment, prevention or screening. for PET-CT has been suggested for detecting distant metastases [28, 29] . Contrast-enhanced intraoperative ultrasound has been shown to improve both the sensitivity of intraoperative ultrasonography to detect LM and the rate of complete resection of hepatic metastases in patients undergoing surgery for CRCLM after chemotherapy [30] .
Consensus recommendations
The panel was unanimous that initial CT has to be performed before and after injection of iodine contrast, and that the use of a low dose to decrease irradiation exposure is not appropriate.
If synchronous CRCLM are initially resectable, liver MRI may be performed in addition to the initial high-quality CT, depending on local expertise and the clinical scenario. PET-CT may be useful for the detection of extrahepatic disease, particularly in patients with recurrent disease or high tumour load (multinodular and/or large metastases) or for whom difficult hepatic resections are planned.
Role of imaging in evaluating response to preoperative treatment
Assessing the response to preoperative treatment (chemotherapy with or without targeted agents) can be judged on tumour size [31, 32] , morphologic changes unrelated to size [33] [34] [35] and metabolic activity [36, 37] . Change in size is a key indicator of response, but limitations encountered with the Response Evaluation Criteria In Solid Tumors (RECIST) have led investigators to explore alternative measures of the impact of chemotherapy on tumour size [38, 39] and to define new parameters such as early tumour shrinkage and depth of response [40, 41] . It has been shown that when treatment includes biological agents, such as bevacizumab, size is a poor predictor of outcome compared with non-size-based morphological criteria [35, 34] . PET-CT is increasingly used to measure response in oncology, but its role when added to cross-sectional imaging to assess response in CRC metastases needs to be further explored [36, 37] .
Consensus recommendations
The following information should be provided by the radiologist for evaluating the response to treatment based on CT imaging: s Response based on size criteria. s Response based on morphological criteria. s Assessment of steatosis and signs of portal hypertension. s Evaluation of the predicted future liver remnant in the preoperative setting. Liver MRI is useful in patients with steatosis and to characterize unclear liver lesions, but the value of routine repeat MRI to evaluate response remains unclear.
Pathology and molecular biology
The role of pathology in the management of CRCLM, including synchronous CRCLM, is important in: diagnosing the specific tumour type; assessing the completeness of resection and tumour response; determining non-tumoral injury or reaction to preoperative chemotherapy; and defining tumour behavior in terms of lymphovascular invasion. Thereby, it provides an estimate of prognosis based on the tumour biology coupled with specific identification of biomarkers, such as epidermal growth factor receptor (EGFR, KRAS wild-type expression), vascular endothelial growth factor (VEGF) and the VEGF receptor. As yet, no biological marker has been identified that distinguishes synchronous metastases from metachronous metastases. RAS (NRAS and KRAS) mutations have been associated with worse disease-free and overall survival following CRCLM resection, independent of anti-EGFR therapy [42] [43] [44] .
Identifying patterns of pathological tumour response to chemotherapy is a standard assessment and may guide surgery. The degree of pathological tumour response to chemotherapy is used as a surrogate marker of chemotherapy efficacy and of biological behavior of the tumour, recurrence and survival outcomes. It can also identify adverse effects of chemotherapy, such as chemotherapy-associated sinusoidal injury [45] or steatohepatitis [46] . A complete pathological response is reported in only about 10% of cases [47] [48] [49] [50] . Tumour regression grade [49] , percentage of viable tumour cells [47] and the thickness of the tumour's peripheral rim ('dangerous halo') [50] have all been used to evaluate pathological response. These criteria have been validated in multicentre studies associating response and survival. All but halo thickness have been shown to be prognostic for overall survival [47, 50, 48, 49, 51] . Safe resection margins are a goal of therapy but the optimal margin width remains to be determined; however, most studies indicate a minimal margin of 1 mm [52] . Intrahepatic micrometastases are only visible under a microscope and represent tumour invasion of sinusoids, the portal vein, the hepatic vein, and lymphatic and bile ducts [53, 54] . Micrometastases are separated from CRCLM by a thin rim of normal parenchyma. Their incidence and distance from the tumour seem to increase with the size of CRCLM [53, [55] [56] [57] , but they are usually located within 1 cm of CRCLM. Micrometastases have been less frequently detected in patients receiving preoperative chemotherapy (25%) than in untreated patients (60%), but preoperative chemotherapy does not significantly reduce the distribution of micrometastases [53] . Several studies have shown micrometastases to have a negative impact on outcomes [58, 57, 54] .
It has been hypothesized that metachronous CRCLM have a different biology after failure of FOLFOX compared with after 5-fluorouracil or no chemotherapy. Adjuvant FOLFOX has been associated with a high rate of somatic mutations in CRCLM and inferior outcomes after hepatectomy, including shorter disease-free survival and overall survival, than in the other two groups [59] .
Consensus recommendations
A standardized pathological evaluation report should include information on: the size of the tumour and margin size; toxic effects of therapy on non-tumour tissue; and the presence of micrometastases and a 'dangerous halo' (may indicate worse overall disease biology). Safe resection margins are still a goal of therapy; a minimal surgical clearance margin of 1 mm has been suggested as sufficient.
No biological marker has yet been identified that distinguishes the biology and prognosis of synchronous from metachronous CRCLM. Tumour response to preoperative therapy is evaluated using tumour regression grade and/or pathological response (percentage viable tumour cells). Other scoring systems are available and have prognostic value. Molecular evaluation of LM is playing an increasing role in the evaluation of the biology of CRCLM. RAS (NRAS and KRAS) mutations have been associated with worse disease-free and overall survival after CRCLM resection, independent of anti-EGFR therapy.
Chemotherapy regimens for synchronous resectable metastases
Preoperative chemotherapy for synchronous metastases was advocated by all but one panel member. It was recognized that more evidence is needed to support this non-surgical strategy [60, 61] . It has been suggested that preoperative chemotherapy has the benefit of downsizing unresectable metastases and increasing resectability of originally unresectable metastases, but not of resectable metastases [61] . It might also be useful for assessing tumour sensitivity to chemotherapy in patients with advanced disease. Elevated levels of carcinoembryonic antigen have been shown to be a marker of response to perioperative FOLFOX in patients with resectable CRCLM, regardless of the number of metastatic lesions [62] . One panel member favored liver resection first when disease is initially easily resectable.
Chemotherapy regimens for synchronous unresectable metastases
Chemotherapy regimens in mCRC are now achieving high response rates (>50%) and long median survival ($30 months). Any of the regimens used for the first-line management of advanced CRC are indicated in cases of synchronous LM, including FOLFOXFIRI with or without bevacizumab or anti-EGFR therapy, and doublets plus bevacizumab or anti-EGFR therapy [63] [64] [65] [66] . In patients not responding to first-line chemotherapy, second-line therapy for mCRC with FOLFIRI plus panitumumab can still elicit a treatment response [67] . Resection is possible but not common following second-line treatment [68, 69] . Although there are no evidence-based data to support the use of targeted therapies after resection, if a regimen is effective in the preoperative setting, many teams use the same regimen postoperatively.
Although upfront surgery of the primary tumour is advocated by some [70] , studies have shown that preoperative chemotherapy can delay surgery of an asymptomatic primary tumour in patients with synchronous CRCLM without compromising survival [71] [72] [73] .
Data from the GERCOR database, and also from the Crystal and OPUS studies, suggest that in patients with unresectable disease, the response rate is higher in patients with liver-limited metastases than in those with non-liver-limited metastases (personal communication, Aimery de Gramont) [74] . GERCOR data also suggest that response to second-line therapy does not depend on response to first-line therapy (personal communication, Aimery de Gramont).
With longer overall and median survival rates, indications for surgery are increasing, with R1 surgery (complete tumour resection without safe margins) being justified for patients with a response to preoperative chemotherapy [75, 76] . Following preoperative chemotherapy and resection, adjuvant chemotherapy should be considered. The panel considered the optimal timing for assessment of response to chemotherapy to be every 2 months. These recommendations are in keeping with those from the European Society for Medical Oncology for mCRC, which recommend cytotoxic doublet plus targeted therapy for patients with potentially resectable and unlikely resectable mCRC [77] , and those of the National Institute for Health and Care Excellence (NICE) in England and Wales [78] . Overall, a total duration of 6 months of perioperative (preoperative and adjuvant) chemotherapy is recommended.
Consensus recommendations
All but one panel member favored first-line optimal chemotherapy for patients with potentially resectable synchronous metastatic disease.
Optimal chemotherapy regimens for synchronous CRCLM include doublets (e.g. FOLFOX, FOLFIRI) combined with targeted therapy (e.g. bevacizumab, cetuximab, panitumumab, depending on RAS status), triplets (FOLFOXIRI) and triplets combined with targeted therapy. However, there was a consensus that chemotherapy without targeted therapy could be used for patients with resectable CRCLM in the absence of evidence for biological agents being useful in this setting. As advocated in earlier recommendations for synchronous CRCLM, at least four courses of first-line chemotherapy should be given and, if progression occurs during first-line therapy or only stable disease is achieved after 4 months, second-line treatment should be considered if conversion from borderline or non-resectable metastases to resectability is still the goal [79] . A sequential treatment approach (e.g. adding a third agent to a doublet) may be used to treat patients who are unresponsive to first-line therapy. The optimal timing for assessing response to chemotherapy is considered to be every 2 months. These recommendations are in line with those from the European Society for Medical Oncology for mCRC, which recommends cytotoxic doublet plus targeted therapy for patients with potentially resectable and unlikely resectable mCRC [77] , and those of NICE in England and Wales [78] . Overall, a total duration of 6 months of perioperative (preoperative and adjuvant) chemotherapy is recommended.
Surgery of the primary tumour
Colorectal surgery should be performed by a specialist colorectal surgeon. The quality of surgery is as important for tumours of the rectum as it is for those of the colon and requires total mesocolon/mesorectal excision, lymph node clearance and a good margin of resection. Based on preoperative staging, the surgeon must be aware of the tumour margins before surgery. For rectal cancer, most patients with synchronous CRCLM will have a local tumour burden that requires radiotherapy.
When both the primary tumour and the metastases are resectable, simultaneous resection can be performed in selected patients undergoing limited hepatectomy with similar outcomes to sequential surgery [80, 81, 13] . Simultaneous resection should be discouraged when the hepatectomy would be major (involving three or more segments) or when complex rectal surgery is to be performed, due to significantly higher postoperative mortality and morbidity [82] .
Delaying hepatic resection does not impair survival and may help select those patients most likely to benefit from hepatic resection [83] . When CRC is asymptomatic, the decision for surgery depends on the resectability of CRCLM. When CRCLM are non-resectable, the benefit of resection of the primary tumour without liver resection is debatable, although the results of a meta-analysis have shown a survival benefit [84] ; however, data from this meta-analysis of non-randomized trials are questionable due to potential publication biases. Several RCTs have been started but most have not recruited a sufficient number of patients, and have been stopped prematurely [85] .
Laparoscopy is increasingly being used and is generally feasible for the colon and rectum, but is more difficult if the tumour has invaded adjacent organs or perforated the visceral peritoneum (T4). Compared with conventional surgery, laparoscopy is associated with less pain, better pulmonary function, reduced fatigue, shorter hospital stay and better quality of life [86, 87] . Laparoscopic surgery for colon and rectal cancer provides similar overall and disease-free survival to open surgery [88] . In addition, the incidence of sexual dysfunction and micturition symptoms following rectal cancer surgery by laparoscopy has been reported to be similar to that following open surgery [89] .
Consensus recommendations
Colorectal surgery should be performed by a specialist colorectal surgeon. Laparoscopy is generally feasible for the colon and rectum, with similar outcomes to open surgery, but is more difficult if the tumour has invaded adjacent organs or perforated the visceral peritoneum (T4). For synchronous rectal LM, preoperative radiotherapy is recommended for mid or low rectal tumours, but chemotherapy remains an adequate treatment for LM. When both the primary tumour and the metastases are resectable and uncomplicated, simultaneous resection can be performed in selected patients undergoing limited hepatectomy. When synchronous CRCLM are non-resectable, resection of the asymptomatic primary without liver resection might have benefits.
Surgery of the liver
The classical approach to surgery of synchronous CRCLM has been to perform primary surgery on the primary CRC followed by resection of LM 2-3 months later, with or without chemotherapy in the interval between surgeries. Currently, preoperative chemotherapy is increasingly being used and, if the CRC is asymptomatic, may be administered before surgery of the primary tumour with the aim of downsizing the metastases and improving resectability rates. As mentioned above, simultaneous resections for CRC and synchronous LM have been shown to be favorable in a number of studies, although caution should be exercised for major combined resections or in patients with comorbid conditions, due to the higher risk of mortality and complications related to simultaneous surgery in this setting [80, 81, 13, 82] .
When the primary CRC is asymptomatic, and in particular for those patients requiring neoadjuvant radiotherapy for rectal cancer, liver surgery might be performed first (reverse approach). If both primary rectal cancer radiation and CRCLM chemotherapy are required, initial short-course (5 Â 5 Gy) radiation followed by chemotherapy is recommended. Preoperative chemotherapy is advised to downsize synchronous CRCLM for resection, to minimize the risk of synchronous CRCLM progressing beyond the possibility of cure and to minimize the occurrence of new metastases [90] . Resection of CRCLM should be performed as soon as it appears feasible after tumour shrinkage [91] . When patients receive more than 6 months of aggressive chemotherapy, the risk associated with surgery is increased [92] . Similar outcomes have been reported for patients undergoing a classic (CRC first), combined or reverse (liver-first) surgical strategy for synchronous CRCLM [93] .
Hepatic resection should not be denied to patients with stable disease after optimum chemotherapy, provided there is adequate liver remnant with inflow and outflow preservation. This may be achieved, for example, through advanced techniques such as portal and/or hepatic venous embolization or two-stage hepatectomy [94] [95] [96] . Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) to induce growth of the future liver remnant before liver resections is being investigated, but results to date indicate increased complications and mortality [97] . Data on overall and long-term survival with ALPPS are needed.
In Asia, resectable synchronous CRCLM are more likely to be indicated for upfront simultaneous resection (before chemotherapy) [98] , whereas in Westernized countries, chemotherapy first is the preferred option [78, 77] . One-stage surgery is more frequently performed in Asia, with acceptable short-term outcomes.
Consensus recommendations
Simultaneous surgery of the primary tumour and CRCLM should be reserved for selected patients with both resectable lesions and requiring limited surgical procedures. Preoperative chemotherapy is usually advised to control the metastatic disease and to downsize synchronous CRCLM for resection. The reverse approach (i.e. liver surgery performed first) may be used after preoperative chemotherapy when the CRCLM tumour burden is large and combined resection is not possible. Hepatic resection should not be denied to patients with stable disease after optimum chemotherapy, provided there is adequate liver remnant with vascular inflow and outflow preservation.
o This may be achieved through specific techniques aimed to increase resectability.
Multidisciplinary teams
The last few years have seen a greater awareness of the importance of MDTs. Results from a first prospective study to evaluate the MDT discussion process and its effects on treatment approaches for a variety of gastrointestinal cancers at a US cancer centre have recently been published [99] . Despite 84% of clinicians being certain of their original plan, a change was recommended in 36% of cases, 72% of which involved major changes; there was 77% adherence to the recommended treatments. The potential advantages of an MDT include better patient care and survival outcomes, and improved consistency, continuity, coordination and cost-effectiveness of care [100] [101] [102] . Same-centre management also has benefits over referred-patient management, including a reduced number of interventions, shorter delays in care, better control of chemotherapy and decreased postoperative mortality [103] [104] [105] . This could be of utmost importance in patients with synchronous metastases.
Non-adherence to MDT decisions has been shown to result in a trend toward lower survival rates in lung cancer [106] . A UK study of non-adherence to MDT decisions (15.1% of decisions were not implemented) in gastrointestinal surgery showed the main reasons for non-adherence to be comorbid conditions (43.9%), patient choice (34.2%) and more information becoming available (19.5%) [107] .
Consensus recommendations
A proficient MDT consisting of at least a colorectal surgeon, liver surgeon, medical/gastrointestinal and radiation oncologist, radiologist, nuclear medicine physician and pathologist optimizes the treatment of CRCLM. The treatment should be considered as a whole, from diagnosis to the last treatment at the same centre. It is important to evaluate and analyze the outcomes from MDTs to assess improvements in treatment goals.
The critical impact of the expertise of the team for patient management
Following the mandatory legal requirement for MDT management of all cancer patients in the UK, France, Belgium, Spain and a number of other European countries over the last 10-15 years, there has been a significant overall improvement in outcomes for all patients with stage IV CRC [108, 109] . A specialized MDT dedicated to the management of stage IV CRC is superior to that of a general CRC MDT [110, 111] and should include surgeons specializing in colorectal surgery, hepatobiliary surgery and thoracic surgery, dedicated CRC medical and radiation oncologists, both imaging and interventional radiologists, and dedicated CRC surgical pathologists.
Clinical scenario recommendations for synchronous CRCLM
In clinical practice, the main determinants of the decision-making process are the tumour statuses of both the primary tumour and metastases and, more precisely, the need for emergency surgery of a complicated primary tumour and the resectability of both tumour sites.
Asymptomatic CRC and resectable synchronous CRCLM
This is the most favorable clinical scenario. A panel consensus (10/11, 91%) was reached for chemotherapy to be given preoperatively. Four or six cycles of chemotherapy were recommended. However, data from the LiverMetSurvey show that 5-year survival is not better with chemotherapy first than with surgery of the primary tumour first (42% vs 47%, respectively) (Fig. 2) . It is, however, likely that surgery of the primary tumour first could have been reserved for selected patients with less widespread disease compared with those treated with chemotherapy first.
For mid and low rectal primary tumours, radiotherapy is often needed and one-stage surgery should not be performed. For colonic and upper rectal primary tumours, one-stage surgery is not advocated for complex colonic tumours, for high-risk patients or when hepatectomy is major (P3 segments). Data from the LiverMetSurvey show that irrespective of the status of the primary tumour, one-stage resection of both the primary tumour and metastases is associated with worse 5-year survival (40%) compared with liver-first surgery (47%) or primary-first surgery (44%) (Fig. 3) .
Most panel members (8/12, 67%) considered pre-and postoperative chemotherapy to be equally important; 3/12 (25%) considered preoperative chemotherapy and 1/12 (8%) considered postoperative chemotherapy to be most important. Most participants (9/11, 82%) considered that postoperative chemotherapy could be different to preoperative chemotherapy, and probably less intensive.
In summary, the recommended management is for chemotherapy first, with or without radiotherapy, followed either by surgery in a one-stage procedure (for patients with limited hepatic disease and easy-to-resect primary tumours) or by staged surgery (for other patients). No strong evidence exists, however, to support this expert recommendation of chemotherapy first, as opposed to colon resection first.
Asymptomatic CRC and non-resectable synchronous CRCLM
This second scenario is one of the most frequently observed, and has traditionally been managed with resection of the primary tumour followed by chemotherapy and then surgery of metastases when resectability can be obtained. Treatment has since evolved, and the entire panel agreed that chemotherapy should be administered initially with the aim of achieving resectability of CRCLM. For potentially resectable disease, all were in favor of optimal chemotherapy (doublets plus biologics, or triplets plus biologics). Data from the LiverMetSurvey show no difference in 5-year survival rates between patients receiving chemotherapy first and those undergoing colectomy first, before resection of CRCLM (31% vs 33%, respectively) (Fig. 4) . However, colectomy first may have been reserved for patients with the best prognosis, introducing a bias into the analysis. Three ongoing trials are comparing the management strategies of colectomy first vs chemotherapy first.
All of the panel experts agreed that simultaneous surgery should not be attempted. If CRCLM become resectable, all recommended the reverse approach to surgery (i.e. liver first). Data from the LiverMetSurvey, although not significantly different between strategies, support this approach; 5-year survival rates were 42% for the reverse approach compared with 33% for colon first surgery and 28% for one-stage surgery (Fig. 5) . For rectal cancer, alternative approaches are to begin with short-course radiotherapy for the primary cancer and then chemotherapy for downsizing CRCLM or to administer primary optimal chemotherapy, then radiotherapy and, in the window between irradiation and rectal cancer surgery, resection of CRCLM. For primary colon or rectal tumours that appear unresectable or borderline resectable, in the UK, NICE guidance is that preoperative chemotherapy should not be offered solely to facilitate sphincter-sparing surgery to patients with rectal cancer [78] .
In summary, the consensus is for optimal chemotherapy first, with the aim of making LM resectable. This should then be followed by hepatic surgery and resection of the primary tumour.
Symptomatic CRC and resectable synchronous CRCLM
Patients with symptomatic CRC may have bleeding, obstruction or perforation. Generally, bleeding can be managed with blood transfusions and will often stop after chemotherapy treatment. Most of the expert panel (9/12, 75%) were in agreement that patients with bleeding should undergo preoperative chemotherapy; the others (3/12, 25%) considered that resection of the primary tumour should be undertaken first. For bowel perforation, surgery is required either to remove the tumour when it is easily resectable, such as right hemicolectomy for right-sided colon lesions or sigmoid colectomy for sigmoid lesions, or to create a stoma (left colon) in cases requiring more technical surgery, such as low anterior resection syndrome and total mesorectal excision. The panel was in complete agreement that, if possible, resection of the primary tumour should be performed first under these circumstances.
Stents are an option for colorectal obstruction, but the results have been poor and the panel recommended reserving them only for easily resectable cases, particularly in elderly patients, and not for right colon or rectal surgery or when anti-angiogenic agents are used. This guidance is in line with that provided by the Endoscopy and Cancer Committee of the French Society of Digestive Endoscopy and the French Federation of Digestive Oncology [112] and with UK NICE guidance [78] . For clinically and radiologically proven complete occlusion with distended evidence of obstruction, the panel was in complete agreement that resection of the primary tumour should be performed first; 9/11 (82%) would perform surgery and use a stoma, whilst 2/11 (18%) would use a stent.
In summary, recommendations are for resection of the primary tumour for perforated or occlusive tumours (but not for tumours with bleeding causing anaemia), followed by chemotherapy and then surgery of LM.
Symptomatic CRC and non-resectable synchronous CRCLM
The expert panel considered that the aim of management for patients with symptomatic CRC and non-resectable synchronous CRCLM is to make the LM resectable. The use of stents is not recommended in most patients owing to the high risk of complications (e.g. perforation, migration bleeding, pain). As in the previous clinical scenario, surgery of the primary tumour should be reserved for cases of bowel perforation or occlusion, with systemic chemotherapy used to downsize both metastases and the primary tumour in other scenarios.
In summary, recommendations are for resection of the primary tumour for perforated or occlusive tumours, followed by chemotherapy and then surgery of LM if tumour shrinkage is achieved. For tumours with bleeding causing anaemia, induction chemotherapy is recommended to downsize both the primary tumour and LM, followed by surgery of the site with the most significant tumour load (usually the liver; i.e. reverse approach).
Conclusions
Synchronous CRCLM should be termed 'synchronously detected liver metastases'. This is defined as LM detected at or before the diagnosis of the primary tumour. Synchronous CRCLM may have less favorable cancer biology and be associated with lower expected survival compared with metachronous metastases. Initial high-dose contrast-enhanced CT of the abdomen is recommended to provide information on whether synchronous CRCLM are resectable.
Recommendations have been made for the management of four different clinical scenarios 1. For asymptomatic CRC and resectable synchronous CRCLM, the recommended management is for chemotherapy first, with or without radiotherapy, followed either by surgery in a one-stage procedure (for patients with limited hepatic disease and easy-to-resect primary tumours) or by staged surgery (for other patients). No strong evidence exists, however, to support this expert recommendation of chemotherapy first, as opposed to colon resection first; ongoing trials may provide such evidence. 2. For asymptomatic CRC and non-resectable synchronous CRCLM, the consensus is for optimal chemotherapy first, with the aim of making LM resectable. This should then be followed by hepatic surgery and resection of the primary tumour. 3. For symptomatic CRC and resectable synchronous CRCLM, recommendations are for resection of the primary tumour for perforated or occlusive tumours (but not for tumours with bleeding causing anaemia), followed by chemotherapy and then surgery of LM. 4. For symptomatic CRC and non-resectable synchronous CRCLM, recommendations are for resection of the primary tumour for perforated or occlusive tumours, followed by chemotherapy and then surgery of LM if tumour shrinkage is achieved. For tumours with bleeding causing anaemia, induction chemotherapy is recommended to downsize both the primary tumour and LM, followed by surgery of the site with the most significant tumour load (usually the liver; i.e. reverse approach).
At least four courses of first-line optimal chemotherapy (doublets with targeted therapy or triplets with or without targeted therapy) are recommended for potentially resectable metastatic disease, with assessment of response every 2 months and a total (preoperative and adjuvant) duration of 6 months' systemic therapy. Intra-arterial chemotherapy may be an alternative option and has been associated with good response rates.
It is hoped that the recommendations provided and the treatment plans for the four different clinical scenarios should help to raise the standard of care for patients with synchronous CRCLM.
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